Phaseline

Companies › Nerviano Medical Sciences

Nerviano Medical Sciences: clinical trials, targets and expected readouts

3 active drug programs in 5 registered trials: 5 Phase 1; Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NMS-03305293–Phase 1Small Cell Lung Cancer; Glioblastoma; Ovarian CancerFeb 2027
atamparib
PARP inhibitor
PARP1Phase 1NSCLC AdenocarcinomaJul 2028
NMS-03597812–Phase 1Relapsed/Refractory Acute Myeloid LeukemiaSep 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06931626NMS-03305293Phase 1Small Cell Lung CancerOncologyFeb 2027
NCT04910022NMS-03305293Phase 1GlioblastomaOncologyMay 2027
NCT06930755NMS-03305293Phase 1Ovarian CancerOncologyMay 2027
NCT07374419atamparibPhase 1NSCLC AdenocarcinomaOncologyJul 2028
NCT06549790NMS-03597812Phase 1Relapsed/Refractory Acute Myeloid LeukemiaOncologySep 2029

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology Merck & Co. (MSD) Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group GSK

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.